Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Pyrotinib in HER2+ Urothelial Carcinoma
NCT05318339Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in urothelial carcinoma (UC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05318339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318339.